ImmunoGen Inc.
About ImmunoGen Inc.
ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology. The Company's lead product candidate, mirvetuximab soravtansine, is being advanced to Phase 3 testing for FRα-positive platinum-resistant ovarian cancer, and is also in Phase 1b/2 testing in combination regimens for earlier-stage disease. The Company's ADC technology is used in three other clinical-stage ImmunoGen product candidates, in Roche's marketed product, Kadcyla®, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda.
447 articles with ImmunoGen Inc.
-
ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2006 Financial Results
2/3/2006
-
ImmunoGen, Inc. Announces Achievement Of Milestone In Collaboration With Genentech, Inc.
2/1/2006
-
ImmunoGen, Inc. Announces Conference Call To Discuss Its Second Quarter Fiscal Year 2006 Financial Results
1/26/2006
-
ImmunoGen, Inc. Announces Genentech, Inc. Has Taken Fourth License To Use ImmunoGen's TAP Technology To Develop Novel Anticancer Therapeutics
12/13/2005
-
ImmunoGen, Inc. Announces Presentation Of HuN901-DM1; Clinical Activity Reported Includes Sustained Complete Remission And Stable Disease
11/16/2005
-
ImmunoGen, Inc. Announces Webcast Of Its Presentation At The CIBC World Markets 16th Annual Healthcare Conference
11/7/2005
-
The Day In Review: Biotech Soars, Erasing Monday’s Loss
12/28/2004